• Diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2023 guidance document

• Existing treatment with medium dose ICS/LABA (\>250 to 500 μg/day of fluticasone propionate DPI or equivalent, per GINA 2023 guidance document) for at least 3 months with a stable dose ≥1 month prior to visit 1

• Participants requiring a maximum of 3 controllers for their asthma will be considered eligible for this study

• Pre-bronchodilator FEV1, as defined in the protocol

• Reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 μg albuterol/salbutamol at screening OR a documented history of ≥20% reduction in the FEV1, as defined in the protocol

• Demonstrated adherence to medium dose ICS/LABA on at least 80% of days during the run-in period

• ACQ-5 score ≥1.5 at screening (visit 1)

• History of ≥1 severe exacerbation(s) in the previous year before visit 1, but not in the 30 days immediately preceding visit 1

• Biomarker criteria: Baseline blood eosinophil count ≥300 cells/μL at visit 1 (\

⁃ 90% of population), as defined in the protocol